The obstruction of the PD-L2-RGMb pathway mediated by antibodies, or the conditional deletion of RGMb in T cells, in conjunction with anti-PD-1 or anti-PD-L1 antibodies, promotes anti-tumor responses in various mouse tumor models that are otherwise unresponsive to these treatments. Here, PDCD1LG2 is linked to neoplasm.